367.18 USD
-8.64 (-2.3%)
Last: Feb 10, 2026, 12:01 PM
AMGN gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 523 industry peers in the Biotechnology industry. While AMGN has a great profitability rating, there are quite some concerns on its financial health. AMGN has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
- In the past year AMGN was profitable.
- In the past year AMGN had a positive cash flow from operations.
- AMGN had positive earnings in each of the past 5 years.
- In the past 5 years AMGN always reported a positive cash flow from operatings.
1.2 Ratios
- With an excellent Return On Assets value of 8.51%, AMGN belongs to the best of the industry, outperforming 93.12% of the companies in the same industry.
- AMGN's Return On Equity of 89.06% is amongst the best of the industry. AMGN outperforms 99.24% of its industry peers.
- The Return On Invested Capital of AMGN (16.85%) is better than 96.56% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for AMGN is below the industry average of 18.12%.
- The last Return On Invested Capital (16.85%) for AMGN is above the 3 year average (14.35%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.51% | ||
| ROE | 89.06% | ||
| ROIC | 16.85% |
ROA(3y)6.63%
ROA(5y)7.92%
ROE(3y)88.81%
ROE(5y)106.67%
ROIC(3y)14.35%
ROIC(5y)15.45%
1.3 Margins
- The Profit Margin of AMGN (20.98%) is better than 94.07% of its industry peers.
- In the last couple of years the Profit Margin of AMGN has declined.
- With an excellent Operating Margin value of 34.19%, AMGN belongs to the best of the industry, outperforming 97.51% of the companies in the same industry.
- AMGN's Operating Margin has improved in the last couple of years.
- With an excellent Gross Margin value of 73.30%, AMGN belongs to the best of the industry, outperforming 82.79% of the companies in the same industry.
- In the last couple of years the Gross Margin of AMGN has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 34.19% | ||
| PM (TTM) | 20.98% | ||
| GM | 73.3% |
OM growth 3Y4.6%
OM growth 5Y4.15%
PM growth 3Y-5.54%
PM growth 5Y-5.99%
GM growth 3Y2.93%
GM growth 5Y1.72%
2. Health
2.1 Basic Checks
- AMGN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- AMGN has more shares outstanding than it did 1 year ago.
- AMGN has less shares outstanding than it did 5 years ago.
- Compared to 1 year ago, AMGN has an improved debt to assets ratio.
2.2 Solvency
- The Debt to FCF ratio of AMGN is 6.74, which is on the high side as it means it would take AMGN, 6.74 years of fcf income to pay off all of its debts.
- AMGN's Debt to FCF ratio of 6.74 is amongst the best of the industry. AMGN outperforms 91.59% of its industry peers.
- AMGN has a Debt/Equity ratio of 5.78. This is a high value indicating a heavy dependency on external financing.
- With a Debt to Equity ratio value of 5.78, AMGN is not doing good in the industry: 80.69% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.78 | ||
| Debt/FCF | 6.74 | ||
| Altman-Z | N/A |
ROIC/WACC1.38
WACC12.24%
2.3 Liquidity
- A Current Ratio of 1.14 indicates that AMGN should not have too much problems paying its short term obligations.
- AMGN has a Current ratio of 1.14. This is amonst the worse of the industry: AMGN underperforms 84.51% of its industry peers.
- AMGN has a Quick Ratio of 1.14. This is a bad value and indicates that AMGN is not financially healthy enough and could expect problems in meeting its short term obligations.
- AMGN has a worse Quick ratio (0.90) than 85.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.14 | ||
| Quick Ratio | 0.9 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an nice 10.24% over the past year.
- Measured over the past 5 years, AMGN shows a small growth in Earnings Per Share. The EPS has been growing by 5.65% on average per year.
- Looking at the last year, AMGN shows a quite strong growth in Revenue. The Revenue has grown by 9.95% in the last year.
- AMGN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.65% yearly.
EPS 1Y (TTM)10.24%
EPS 3Y7.29%
EPS 5Y5.65%
EPS Q2Q%-0.38%
Revenue 1Y (TTM)9.95%
Revenue growth 3Y11.77%
Revenue growth 5Y7.65%
Sales Q2Q%8.58%
3.2 Future
- AMGN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.03% yearly.
- AMGN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.56% yearly.
EPS Next Y3.12%
EPS Next 2Y3.35%
EPS Next 3Y2.5%
EPS Next 5Y4.03%
Revenue Next Year2.04%
Revenue Next 2Y2.46%
Revenue Next 3Y1.68%
Revenue Next 5Y2.56%
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- AMGN is valuated correctly with a Price/Earnings ratio of 16.80.
- AMGN's Price/Earnings ratio is rather cheap when compared to the industry. AMGN is cheaper than 95.79% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 28.06, AMGN is valued a bit cheaper.
- The Price/Forward Earnings ratio is 16.30, which indicates a correct valuation of AMGN.
- 95.22% of the companies in the same industry are more expensive than AMGN, based on the Price/Forward Earnings ratio.
- AMGN's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.86.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.8 | ||
| Fwd PE | 16.3 |
4.2 Price Multiples
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of AMGN indicates a rather cheap valuation: AMGN is cheaper than 94.65% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.41 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- The excellent profitability rating of AMGN may justify a higher PE ratio.
PEG (NY)5.38
PEG (5Y)2.97
EPS Next 2Y3.35%
EPS Next 3Y2.5%
5. Dividend
5.1 Amount
- With a Yearly Dividend Yield of 2.68%, AMGN has a reasonable but not impressive dividend return.
- AMGN's Dividend Yield is rather good when compared to the industry average which is at 1.14. AMGN pays more dividend than 98.85% of the companies in the same industry.
- AMGN's Dividend Yield is a higher than the S&P500 average which is at 1.80.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.68% |
5.2 History
- On average, the dividend of AMGN grows each year by 9.41%, which is quite nice.
- AMGN has been paying a dividend for at least 10 years, so it has a reliable track record.
- AMGN has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)9.41%
Div Incr Years13
Div Non Decr Years13
5.3 Sustainability
- AMGN's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP0%
EPS Next 2Y3.35%
EPS Next 3Y2.5%
NASDAQ:AMGN (2/10/2026, 12:01:09 PM)
367.18
-8.64 (-2.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-03 2026-02-03/amc
Earnings (Next)04-29 2026-04-29/amc
Inst Owners83.87%
Inst Owner Change-1.4%
Ins Owners0.06%
Ins Owner Change-0.79%
Market Cap197.72B
Revenue(TTM)36.75B
Net Income(TTM)7.71B
Analysts72.2
Price Target341.81 (-6.91%)
Short Float %2.6%
Short Ratio4.96
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.68% |
Yearly Dividend9.01
Dividend Growth(5Y)9.41%
DP0%
Div Incr Years13
Div Non Decr Years13
Ex-Date02-13 2026-02-13 (2.52)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.92%
Min EPS beat(2)9.56%
Max EPS beat(2)10.28%
EPS beat(4)4
Avg EPS beat(4)10.8%
Min EPS beat(4)9.56%
Max EPS beat(4)11.73%
EPS beat(8)7
Avg EPS beat(8)6.29%
EPS beat(12)11
Avg EPS beat(12)5.41%
EPS beat(16)14
Avg EPS beat(16)4.51%
Revenue beat(2)2
Avg Revenue beat(2)3.3%
Min Revenue beat(2)2.11%
Max Revenue beat(2)4.49%
Revenue beat(4)3
Avg Revenue beat(4)1.61%
Min Revenue beat(4)-0.84%
Max Revenue beat(4)4.49%
Revenue beat(8)4
Avg Revenue beat(8)0.19%
Revenue beat(12)5
Avg Revenue beat(12)-0.22%
Revenue beat(16)6
Avg Revenue beat(16)-0.27%
PT rev (1m)2.13%
PT rev (3m)6.94%
EPS NQ rev (1m)0.84%
EPS NQ rev (3m)0.68%
EPS NY rev (1m)0.6%
EPS NY rev (3m)2.41%
Revenue NQ rev (1m)-0.2%
Revenue NQ rev (3m)0.27%
Revenue NY rev (1m)0.3%
Revenue NY rev (3m)2.09%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.8 | ||
| Fwd PE | 16.3 | ||
| P/S | 5.38 | ||
| P/FCF | 24.41 | ||
| P/OCF | 19.86 | ||
| P/B | 22.84 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)21.85
EY5.95%
EPS(NY)22.53
Fwd EY6.14%
FCF(TTM)15.04
FCFY4.1%
OCF(TTM)18.49
OCFY5.04%
SpS68.25
BVpS16.08
TBVpS-59.98
PEG (NY)5.38
PEG (5Y)2.97
Graham Number88.91
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.51% | ||
| ROE | 89.06% | ||
| ROCE | 19.3% | ||
| ROIC | 16.85% | ||
| ROICexc | 19.6% | ||
| ROICexgc | 73.08% | ||
| OM | 34.19% | ||
| PM (TTM) | 20.98% | ||
| GM | 73.3% | ||
| FCFM | 22.04% |
ROA(3y)6.63%
ROA(5y)7.92%
ROE(3y)88.81%
ROE(5y)106.67%
ROIC(3y)14.35%
ROIC(5y)15.45%
ROICexc(3y)16.88%
ROICexc(5y)18.44%
ROICexgc(3y)72.7%
ROICexgc(5y)79.08%
ROCE(3y)16.43%
ROCE(5y)17.69%
ROICexgc growth 3Y-3.21%
ROICexgc growth 5Y2.03%
ROICexc growth 3Y4.63%
ROICexc growth 5Y5.17%
OM growth 3Y4.6%
OM growth 5Y4.15%
PM growth 3Y-5.54%
PM growth 5Y-5.99%
GM growth 3Y2.93%
GM growth 5Y1.72%
F-Score7
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.78 | ||
| Debt/FCF | 6.74 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 5.06% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | N/A | ||
| Profit Quality | 105.05% | ||
| Current Ratio | 1.14 | ||
| Quick Ratio | 0.9 | ||
| Altman-Z | N/A |
F-Score7
WACC12.24%
ROIC/WACC1.38
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)4.09%
Cap/Sales(5y)3.84%
Profit Quality(3y)156.25%
Profit Quality(5y)149.01%
High Growth Momentum
Growth
EPS 1Y (TTM)10.24%
EPS 3Y7.29%
EPS 5Y5.65%
EPS Q2Q%-0.38%
EPS Next Y3.12%
EPS Next 2Y3.35%
EPS Next 3Y2.5%
EPS Next 5Y4.03%
Revenue 1Y (TTM)9.95%
Revenue growth 3Y11.77%
Revenue growth 5Y7.65%
Sales Q2Q%8.58%
Revenue Next Year2.04%
Revenue Next 2Y2.46%
Revenue Next 3Y1.68%
Revenue Next 5Y2.56%
EBIT growth 1Y73.11%
EBIT growth 3Y16.9%
EBIT growth 5Y12.12%
EBIT Next Year31.54%
EBIT Next 3Y9.81%
EBIT Next 5Y8.24%
FCF growth 1Y-22.07%
FCF growth 3Y-2.67%
FCF growth 5Y-3.91%
OCF growth 1Y-13.33%
OCF growth 3Y0.81%
OCF growth 5Y-1.05%
AMGEN INC / AMGN FAQ
Can you provide the ChartMill fundamental rating for AMGEN INC?
ChartMill assigns a fundamental rating of 5 / 10 to AMGN.
What is the valuation status of AMGEN INC (AMGN) stock?
ChartMill assigns a valuation rating of 5 / 10 to AMGEN INC (AMGN). This can be considered as Fairly Valued.
What is the profitability of AMGN stock?
AMGEN INC (AMGN) has a profitability rating of 8 / 10.
How financially healthy is AMGEN INC?
The financial health rating of AMGEN INC (AMGN) is 3 / 10.
What is the earnings growth outlook for AMGEN INC?
The Earnings per Share (EPS) of AMGEN INC (AMGN) is expected to grow by 3.12% in the next year.